Marcus A. Woerns

Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: A double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme

Markus Moehler, Annett Maderer, C Schimanski et al. · European Journal of Cancer · 2014 · 135 citations · Full text

Medicine, Oncology, Pharmacology +11

Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program

Markus Moehler, Annett Maderer, Anne Ehrlich et al. · BMC Cancer · 2019 · 46 citations · Full text

Medicine, Oncology, Pharmacology +16

A randomized, double-blind, multicenter phase II AIO trial with gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with chemotherapy-naive advanced or metastatic biliary tract cancer: First safety and efficacy data.

Markus Moehler, Carl Christoph Schimanski, S Kanzler et al. · Journal of Clinical Oncology · 2011 · 13 citations

Medicine, Oncology, Pharmacology +14

Inclusion of targeted therapies in the standard of care for metastatic colorectal cancer patients in a German cancer center: the more the better?!

Markus Moehler, Thomas Thomaidis, Chourouk Zeifri et al. · Journal of Cancer Research and Clinical Oncology · 2014 · 11 citations · Full text

Medicine, Oncology, Surgery +11

Validation of insulin-like growth factor-1 as a prognostic parameter in patients with hepatocellular carcinoma in a European cohort

Yvonne Huber, Franziska Bierling, Christian Labenz et al. · BMC Cancer · 2018 · 11 citations · Full text

Medicine, Oncology, Gastrointestinal Oncology +16